encorafenib

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2018
02420142018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
PURPOSE OF REVIEW To describe the pharmacological properties, preclinical and clinical data of the novel V-Raf Murine Sarcoma… (More)
  • figure 1
  • table 1
  • figure 2
Is this relevant?
2018
2018
Encorafenib (LGX818) is a promising BRAFV600E inhibitor that has efficacy against metastatic melanoma. To better understand its… (More)
Is this relevant?
2017
2017
Preclinical evidence suggests that concomitant BRAF and EGFR inhibition leads to sustained suppression of MAPK signaling and… (More)
Is this relevant?
2017
2017
Purpose: Encorafenib, a selective BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other… (More)
Is this relevant?
2017
2017
Purpose: NRAS mutations in malignant melanoma are associated with aggressive disease requiring rapid antitumor intervention, but… (More)
Is this relevant?
2016
2016
Cutaneous toxicities under therapy with selective BRAF inhibitors such as vemurafenib or encorafenib (LGX818) are frequent… (More)
  • table 1
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
2016
2016
BRAF inhibitor (BRAFi) therapy is associated with the induction of neoplasia, most commonly cutaneous squamous cell carcinoma… (More)
  • figure 1
  • table 1
  • figure 2
Is this relevant?
Review
2016
Review
2016
The efficacy of molecular-targeted agent combinations for the treatment of metastatic colorectal cancer has become increasingly… (More)
Is this relevant?
2015
2015
BACKGROUND Treatment with selective BRAF or MEK inhibitors is frequently associated with cutaneous toxicities, including squamous… (More)
Is this relevant?
2014
2014
BACKGROUND Melanoma is one of the most aggressive skin cancers. Recently, selective MEK inhibitors have shown efficacy in… (More)
Is this relevant?